CCR7 DC Define a Type 17 Module in Psoriasis

Yang Sun,Fangzhou Lou,Xiaojie Cai,Zhikai Wang,Xiuli Yang,Libo Sun,Zhouwei Wu,Zhaoyuan Liu,Yu-Ling Shi,Florent Ginhoux,Honglin Wang

DOI: https://doi.org/10.1101/2024.04.28.591489

2024-04-30

Abstract:Interleukin (IL)-23 is the master pathogenic cytokine in psoriasis and neutralization of IL-23 alleviates psoriasis. Psoriasis relapses after the withdrawal of IL-23 antibodies, and the persistence of IL-23-producing cells probably contributes to such recurrence. However, the cellular source of IL-23 was unclear, which hinders the development of targeted therapies focusing on modulating IL-23 expression aimed at resolving relapse. Here, we showed that dendritic cells (CCR7 DC) dominantly produced IL-23 by concomitantly expressing the IL-23A and IL-12B subunits in human psoriatic skin. Deletion of CCR7 DC completely abrogated IL-23 production in a mouse model of psoriasis and enforced expression of IL-23a in CCR7 DC elicited not only αβT cell-driven psoriasis-like skin disease, but also arthritis. CCR7 DC co-localized with CD161 IL-17-producing T cells and KRT17 keratinocytes, which were located in the outermost layers of psoriatic epidermis and strongly exhibited IL-17 downstream signatures. Based on these data, we identified CCR7 DC as the source of IL-23 in psoriasis, which paves the way for the design of therapies focused on manipulating IL-23 production that may resolve the relapse of chronic inflammatory disorders like psoriasis.

Immunology

What problem does this paper attempt to address?

The key problem that this paper attempts to solve lies in determining the main source cells of IL - 23 in psoriasis (psoriasis), in order to provide new treatment strategies for preventing disease recurrence. Specifically, researchers are concerned with: 1. **Defining the cellular source of IL - 23**: Although it is known that IL - 23 is a key pathogenic cytokine in psoriasis and neutralizing IL - 23 can relieve symptoms, the specific cells that produce IL - 23 are still unclear. This uncertainty has hindered the development of targeted therapies for regulating IL - 23 expression. 2. **Solving the recurrence problem**: Psoriasis patients often relapse after stopping the use of IL - 23 antibodies, which may be due to the persistent existence of IL - 23 - producing cells. Therefore, identifying and regulating these cells are crucial for preventing recurrence. ### Main findings of the study Through single - cell transcriptomics analysis and other experimental methods, researchers have found: - **CCR7+ DC are the main IL - 23 producers**: In human psoriasis skin, CCR7+ DC (dendritic cells expressing IL4I1, CD200 and CCR7) simultaneously express IL - 23A and IL - 12B subunits, which are two components necessary for forming complete IL - 23. - **CCR7+ DC may be derived from cDC2**: By performing lineage tracing on different types of dendritic cells, the study found that CCR7+ DC are similar to cDC2 at the transcriptional level, suggesting that they may be differentiated from cDC2. - **The spatial distribution of CCR7+ DC defines a type 17 module**: CCR7+ DC co - localize with CD161+ IL - 17 - producing T cells and KRT17+ keratinocytes, forming a spatial type 17 module. These cells are located in the outer layer of the psoriasis epidermis and exhibit strong IL - 17 downstream signaling characteristics. ### Experimental verification To further verify the above findings, researchers used the IMQ - induced mouse psoriasis model: - **Deletion of CCR7+ DC leads to the disappearance of IL - 23 signals**: By deleting CCR7+ DC, researchers have proven that these cells are indeed the main source of IL - 23 in the mouse model. - **Over - expression of IL - 23a in CCR7+ DC induces psoriasis - like skin inflammation**: Mice with specific over - expression of IL - 23a in CCR7+ DC showed pathological features similar to human psoriasis, including epidermal thickening, abnormal proliferation of keratinocytes, etc. In summary, this study has identified CCR7+ DC as the main source of IL - 23 in psoriasis and revealed its potential role in disease recurrence, providing an important basis for further developing targeted treatment strategies.

CCR7 DC Define a Type 17 Module in Psoriasis

Epigenetic Regulation of IL-23 by E3 Ligase FBXW7 in Dendritic Cells is Critical for Psoriasis-like Inflammation.

A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response

IL-17C Amplifies Epithelial Inflammation in Human Psoriasis and Atopic Eczema

Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation

Pivotal Role of Dermal IL-17-Producing Γδ T Cells in Skin Inflammation

C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis

Dendritic cells: The driver of psoriasis

IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis

Failure of Plasmacytoid Dendritic Cells to Drive Functional Regulatory T Cell Differentiation In Human Disease

Inducible nitric oxide synthase-expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis

IL23R mutations associated with decreased risk of psoriasis lead to the differential expression of genes implicated in the disease

Nitric oxide supplementation alleviates ammonium toxicity in the submerged macrophyte Hydrilla verticillata (L.f.) Royle.

Human IL-23R Cytokine-Binding Homology Region-Fc Fusion Protein Ameliorates Psoriasis via the Decrease of Systemic Th17 and ILC3 Cell Responses

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.

An Autocrine Circuit of IL-33 in Keratinocytes Is Involved in the Progression of Psoriasis

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

[Derivatives of phenylbutyrates. 3. Synthesis of compounds with potential anti-inflammatory activity correlated to 3,3'-diphenyl-N,N'-dipyrrolidine-2,2'-dione].